Wire · opportunities
Stage 4 Maine cancer patient says new FDA-approved pill is buying him time
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 28 August 2026 · Fusion42 review
The FDA has approved Rasonque, a new pill targeting the KRAS protein, providing a significant survival extension for pancreatic cancer patients compared to traditional chemotherapy.
This Wire brief sits within Fusion42's coverage of Biotech, and 39 sources have reported it between 26 Aug 2026 and 28 Aug 2026.
◆ ◆ The Wire takeaway
FDA clearance for a novel KRAS inhibitor opens a new treatment path that shifts pancreatic cancer care from chemotherapy to oral targeted therapies. If you work in cancer drug development, this sets a precedent for accelerating approval of molecular targeted pills.
◆ Coverage
39 sources · first reported 26 Aug 2026 · latest 28 Aug 2026
◆ Topics